Applied DNA Sciences develops and markets DNA-based technology solutions utilizing its LinearDNA polymerase chain reaction (PCR) based manufacturing platform. Co.'s proprietary platform produces DNA for use in nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing market and for supply chain security, anti-counterfeiting and anti-theft technology purposes. In addition, Co. has developed a PCR-based molecular diagnostic test for SARS-CoV-2 (COVID-19). Co. manufactures and sells its Emergency Use Authorization authorized COVID-19 molecular diagnostic test kit under the Linea COVID-19 Assay Kit. We show 37 historical shares outstanding datapoints in our APDN shares outstanding history coverage, used to compute APDN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing APDN market cap history over the course of time is important for investors
interested in comparing APDN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of APDN versus a peer is one thing; comparing
APDN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like APDN can fluctuate over the course of history.
With this page we aim to empower investors researching APDN by allowing them to research the APDN market cap history. |